Bioceltix Statistics

Total Valuation

Bioceltix has a market cap or net worth of PLN 457.48 million. The enterprise value is 433.64 million.

Market Cap	457.48M
Enterprise Value	433.64M

Important Dates

The last earnings date was Thursday, November 27, 2025.

Earnings Date	Nov 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Bioceltix has 4.92 million shares outstanding.

Current Share Class	4.92M
Shares Outstanding	4.92M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	7.43%
Owned by Institutions (%)	23.72%
Float	3.83M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	16.94
P/TBV Ratio	16.94
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-29.32
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-33.04

Financial Position

The company has a current ratio of 8.83, with a Debt / Equity ratio of 0.00.

Current Ratio	8.83
Quick Ratio	8.82
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.01
Interest Coverage	-80.60

Financial Efficiency

Return on equity (ROE) is -43.22% and return on invested capital (ROIC) is -27.12%.

Return on Equity (ROE)	-43.22%
Return on Assets (ROA)	-25.28%
Return on Invested Capital (ROIC)	-27.12%
Return on Capital Employed (ROCE)	-55.44%
Revenue Per Employee	n/a
Profits Per Employee	-410,784
Employee Count	36
Asset Turnover	n/a
Inventory Turnover	84.10

Taxes

Income Tax	-51,492
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +19.10% in the last 52 weeks. The beta is 1.23, so Bioceltix's price volatility has been higher than the market average.

Beta (5Y)	1.23
52-Week Price Change	+19.10%
50-Day Moving Average	96.10
200-Day Moving Average	103.12
Relative Strength Index (RSI)	48.33
Average Volume (20 Days)	4,819

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-1.79M
Operating Income	-15.08M
Pretax Income	-14.84M
Net Income	-14.79M
EBITDA	-14.35M
EBIT	-15.08M
Earnings Per Share (EPS)	n/a

Full Income Statement

Balance Sheet

The company has 23.95 million in cash and 113,301 in debt, giving a net cash position of 23.84 million or 4.84 per share.

Cash & Cash Equivalents	23.95M
Total Debt	113,301
Net Cash	23.84M
Net Cash Per Share	4.84
Equity (Book Value)	27.00M
Book Value Per Share	n/a
Working Capital	23.26M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -11.49 million and capital expenditures -1.64 million, giving a free cash flow of -13.13 million.

Operating Cash Flow	-11.49M
Capital Expenditures	-1.64M
Free Cash Flow	-13.13M
FCF Per Share	-2.67

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Bioceltix does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-3.23%
FCF Yield	-2.87%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1